Frenalyn Domingo, NP
Nurse Practitioner · Grand Terrace, CANPI 1588685226
Payments from drug & device makers
Across 48 payments — averaging $104.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$797
- AstraZeneca$265
- Abbott$252
- Lilly USA, LLC$247
- Otsuka America Pharmaceutical, Inc.$233
- Boehringer Ingelheim$230
- plus $3K from 25 others
What the payments were for
- Food & beverage$5,033100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $797 |
| AstraZeneca | 3 | $265 |
| Abbott | 2 | $252 |
| Lilly USA, LLC | 2 | $247 |
| Otsuka America Pharmaceutical, Inc. | 3 | $233 |
| Boehringer Ingelheim | 2 | $230 |
| Gilead | 2 | $207 |
| Sanofi-aventis U.S. LLC | 2 | $184 |
| Aspira Women's Health Inc | 1 | $152 |
| Edwards Lifesciences | 1 | $150 |
| Abiomed | 1 | $147 |
| Si-bone, Inc. | 1 | $144 |
| Averitas Pharma Inc. | 1 | $128 |
| Hologic Sales And Service, LLC | 1 | $128 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| UCB, Inc. | 1 | $125 |
| ZOLL Respicardia, Inc. | 1 | $125 |
| Alkermes, Inc. | 1 | $125 |
| Genentech USA, Inc. | 1 | $124 |
| Argenx US, Inc. | 1 | $122 |
| Novo Nordisk | 1 | $122 |
| Amgen | 1 | $121 |
| Astellas Pharma US Inc | 1 | $118 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $115 |
| E.r. Squibb & Sons, L.L.C. | 1 | $104 |
| Acadia Pharmaceuticals Inc | 1 | $93 |
| Hydrofera LLC | 1 | $91 |
| Teva Pharmaceuticals USA, Inc. | 1 | $59 |
| Galderma Laboratories, L.p. | 2 | $47 |
| Smith+Nephew | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,033 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,695 |
| Divalproex Sodium | 12 | $2,910 |
| Carbamazepine ErCarbamazepine | 20 | $2,081 |
| Albuterol Sulfate | 13 | $1,870 |
| Memantine Hcl ErMemantine Hcl | 12 | $1,042 |
| Levetiracetam | 27 | $956 |
| Trazodone Hcl | 38 | $757 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $710 |
| Levothyroxine Sodium | 52 | $602 |
| Fluvoxamine Maleate | 13 | $597 |
| Bicalutamide | 13 | $519 |
| AmantadineAmantadine Hcl | 13 | $507 |
| Omeprazole | 26 | $400 |
| Atorvastatin Calcium | 26 | $378 |
| Quetiapine Fumarate | 24 | $369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimStiolto Respimat | $230 | $6,69513 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $59 | $1,87013 claims |
| Lilly USA, LLCOlanzapine | $247 | $13514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Grand Terrace
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$899K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.